ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0477

TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
Abstract Number: 0478

Identification of Clinical Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering Method
Abstract Number: 0479

A Novel Semi-automated Classifier of Radiographic Hip Osteoarthritis on DXA Scans Is Strongly Predictive of Pain, Clinical Diagnosis and Joint Replacement: Findings from 40,000 Participants in UK Biobank
Abstract Number: 0480

Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis
Abstract Number: 0481

The Day-to-day Variability of Pain and the Relationship with Physical Activity in People with Knee Osteoarthritis: A Longitudinal, Observational Feasibility Study
Abstract Number: 0482

Metformin Use Reduces the Risk of Developing Osteoarthritis: A Propensity Score Matching Study
Abstract Number: 0483

Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
Abstract Number: 0484

RheumMadness: Creating an Online Community of Inquiry
Abstract Number: 0485

The Impact of COVID-19 on Rheumatology Trainee Health and Wellbeing: Results from the COVID-19 Global Rheumatology Alliance Trainee Survey
Abstract Number: 0486

A Practical Approach to Competency-based Evaluations and Milestone Mapping for Adult Rheumatology Fellowship Programs
Abstract Number: 0487

A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors
Abstract Number: 0488

Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Abstract Number: 0489

CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Abstract Number: 0490

Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
Abstract Number: 0491

Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].